Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 5/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30588163 | 0.88 | AR (0.53) | PGRAREPHX2 | |
| SCHEMBL20046662 | 0.87 | PGR (0.62) | PGRARDRD2EPHX2 | |
| SCHEMBL28538027 | 0.87 | PGR (0.62) | PGRARDRD2EPHX2 | |
| SCHEMBL29546606 | 0.87 | PGR (0.62) | PGRARDRD2EPHX2 | |
| SCHEMBL31604723 | 0.87 | PGR (0.46) | PGRARDRD2GPR119AAK1 | |
| SCHEMBL20046695 | 0.87 | PGR (0.62) | PGRARDRD2EPHX2 | |
| SCHEMBL6154808 | 0.86 | SUV39H2 (0.46) | PGRARDRD2GPR119 | |
| SCHEMBL31515461 | 0.86 | EPHX2 (0.48) | PGRARDRD2EPHX2 | |
| SCHEMBL6153458 | 0.83 | KDM4D (0.49) | KDM4DTRPA1DRD2GPR119AAK1 | |
| SCHEMBL6153457 | 0.83 | KDM4D (0.49) | KDM4DTRPA1DRD2GPR119AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | KDM4D 2098/4885TRPA1 691/4885PGR 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.